The influence of CYP2C19 loss-of-function alleles on atherothrombotic events in patients on clopidogrel after endovascular aneurysm repair (EVAR)
- Conditions
- Abdominal Aortic Aneurysm
- Registration Number
- NL-OMON29281
- Lead Sponsor
- ot applicable
- Brief Summary
ot applicable
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 300
Adult patients (age 18 years)
- Obtained written informed consent
- Patients with the ability to perform a buccal swab at home
- Patients who underwent EVAR for an infrarenal AAA between January 2016 and April 2020, including those that were additionally treated with an iliac branched device and/or coiling of the internal iliac artery
- Patients who are on continues treatment with clopidogrel as single antiplatelet therapy since EVAR
- Patients with a known CYP2C19 genotype or metabolizer state
- Patients who are treated with other anticoagulants such as aspirin, ticagrelor, prasugrel, coumarins or Non vitamin K Oral Anti-Coagulants (NOACs)
- Patient treated for a juxtarenal AAA with Fenestrated EVAR, Chimney EVAR or open surgical repair
- Patients that have used clopidogrel only temporary after EVAR
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome will be the occurrence of adverse clinical events related to arterial thrombosis such as incidence of Major Adverse Cardiovascular Events (MACE) and Major Adverse Limb events (MALE).
- Secondary Outcome Measures
Name Time Method The incidence of in-stent thrombosis, mural thrombosis and bleeding complications